Think It's Too Late to Buy Tempus AI Stock? Here's the Biggest Reason Why There's Still Time.

Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since Jan. 1. In light of the artificial intelligence (AI) stock's strong performance so far this year, prospective investors may fear there's not much share price growth potential left for Tempus, an innovator in applying AI solutions to the healthcare industry.But this bearish conclusion fails to properly acknowledge that there's plenty of fuel left in the tank which could help to propel Tempus stock even higher in the months and years to come.While Tempus AI's rise is impressive, it's foolhardy to conclude that the potential for further growth has evaporated. The company recently completed its acquisition of Ambry Genetics, providing Tempus AI with the ability to offer patients more comprehensive cancer screening with Ambry's hereditary cancer assay. Additionally, Tempus AI now has the ability to expand into other healthcare areas after acquiring Ambry, including pediatrics, reproductive health, and immunology.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool